




Contents lists available at ScienceDirect

## Neurobiology of Aging

journal homepage: [www.elsevier.com/locate/neuaging](http://www.elsevier.com/locate/neuaging)

## Brief communication

## Degree of cognitive impairment does not signify early versus late mild cognitive impairment: confirmation based on Alzheimer's disease polygenic risk

Jeremy A. Elman<sup>a,b,\*</sup>, Eero Vuoksimaa<sup>c</sup>, Carol E. Franz<sup>a,b</sup>, William S. Kremen<sup>a,b,d</sup>, for the Alzheimer's Disease Neuroimaging Initiative<sup>1</sup><sup>a</sup> Department of Psychiatry, University of California San Diego, La Jolla, CA, USA<sup>b</sup> Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA, USA<sup>c</sup> Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland<sup>d</sup> Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, La Jolla, CA, USA

## ARTICLE INFO

## Article history:

Received 6 March 2020

Received in revised form 28 May 2020

Accepted 31 May 2020

Available online 11 June 2020

## Keywords:

Alzheimer's disease (AD)

Mild cognitive impairment (MCI)

Polygenic risk scores (PRS)

Diagnostic criteria

## ABSTRACT

Degree of memory impairment is often used to infer early versus late amnesic mild cognitive impairment (aMCI). Previously, 318 Alzheimer's Disease Neuroimaging Initiative participants with aMCI—determined by a single memory test—were divided based on Rey Auditory Verbal Learning Task (AVLT) delayed recall: AVLT-impaired ( $n = 225$ ) and AVLT-normal ( $n = 93$ ). Equally consistent with differential progression or differential diagnosis, the AVLT-impaired group had more abnormal Alzheimer's disease (AD) biomarkers, more neurodegeneration over time, and was more likely to develop AD. In the present study, higher AD polygenic risk scores were associated with increased odds of being AVLT-impaired (odds ratio 1.8,  $p < 0.001$ ). Thus, impairment severity does not necessarily reflect early versus late aMCI because disease progression cannot alter polygenic risk. Presumed early MCI is likely a heterogeneous category that includes excess false-positives. The additional cognitive test improved diagnostic precision by reducing false positives. Impairment severity may reflect differences in underlying disease risk but cannot be used to infer early versus late MCI based on cross-sectional data alone.

© 2020 Elsevier Inc. All rights reserved.

## 1. Introduction

Mild cognitive impairment (MCI) is a heterogeneous condition, and it is important to reduce false-positive diagnoses that may be applied to those not on the Alzheimer's disease (AD) continuum. Vuoksimaa et al. (2018) assessed Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with amnesic MCI (aMCI). The

cognitive criterion for aMCI in ADNI is impairment on Wechsler Logical Memory delayed recall. Modifying the criteria to also require impairment on Rey Auditory Verbal Learning Task (AVLT) delayed recall was associated with more abnormal AD biomarkers and substantially increased progression to AD. The most common explanation is that impairment on the additional test is simply identifying individuals further along on the disease trajectory who have been subject to more cognitive decline and accumulation of pathology—sometimes referred to as early versus late MCI. However, those results are equally consistent with an alternative possibility that the AVLT-normal group contains excess false positives who were simply at lower underlying disease risk and therefore less likely to progress. Put another way, we ask the question: Does this represent different disease stage or differential diagnosis?

Genetic information can provide a key piece of evidence to distinguish between these possibilities. If the groups differ because one has progressed further than the other along the disease trajectory, they should not differ in their genetic risk for AD. If, on the other hand, the AVLT-normal group contains excess false positives, they should have lower AD genetic risk. To address this issue, we

Jeremy A. Elman and Eero Vuoksimaa contributed equally to the manuscript.

Declarations of interest: None.

\* Corresponding author at: Department of Psychiatry, University of California San Diego, 9500 Gilman Drive (MC 0738), La Jolla, CA 92093, USA. Tel.: +1 858 534 6842; fax: +1 858 822 5856.

E-mail address: [jaelman@health.ucsd.edu](mailto:jaelman@health.ucsd.edu) (J.A. Elman).

<sup>1</sup> Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf).

build on the findings of Vuoksimaa et al. (2018) by testing for group differences on an AD polygenic risk score (PRS).

## 2. Materials and methods

### 2.1. Participants

Data used in the preparation of this article were obtained from the ADNI database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD.

The present study included 318 participants from the ADNI-1 who fulfilled criteria for aMCI at baseline, had AVLT data, and had good quality genotyping data. This represents a subset of the individuals included in our previous analysis (Vuoksimaa et al., 2018). Demographic characteristics included age, sex, education, and American National Adult Reading Test scores (a measure of estimated premorbid cognitive ability). Procedures were approved by the Institutional Review Board of participating institutions. Informed consent was obtained from all participants.

### 2.2. Mild cognitive impairment subtypes

As described previously (Vuoksimaa et al., 2018), ADNI participants were diagnosed with aMCI according to Petersen et al. (2010) criteria:  $\geq 1.5$  standard deviations below the education-adjusted mean on Wechsler Logical Memory Story A delayed recall; subjective memory complaint; Clinical Dementia Rating Scale score of 0.5; and Mini-Mental State Exam score  $\geq 24$ . We then categorized these baseline aMCI cases based on whether they were also impaired on AVLT delayed recall, defined by a cutoff of 1 standard deviation below normative means: AVLT-normal (scaled score  $\geq 8$ ) and AVLT-impaired (scaled score  $\leq 7$ ).

### 2.3. Polygenic risk scores

Genotyping was done using the Illumina Human610-Quad BeadChip (Illumina, San Diego, CA) (Saykin et al., 2010) and imputed using the 1000 Genomes Phase 3 European population data as a reference panel (The 1000 Genomes Project Consortium, 2015). The AD-PRS was computed with PRSice-2 (Choi and O'Reilly, 2019) using summary data of an AD genome-wide association study meta-analysis (Lambert et al., 2013). We excluded rare single nucleotide polymorphisms (SNPs) (minor allele frequency  $< 1\%$ ) and SNPs with poor imputation quality ( $R^2 < 0.5$ ) from the calculation. SNPs were trimmed for linkage disequilibrium (LD) ( $r^2$  threshold of 0.2 in a 500 kb window) based on LD patterns in the 1000 Genomes EUR cohort. Scores were calculated from SNPs based on a  $p$ -value threshold of  $< 0.50$ , as this has been shown to provide optimal case-control discrimination in previous studies (Escott-Price et al., 2015, 2017; Logue et al., 2019). An additional “No APOE” version of the AD-PRS was calculated excluding the region of LD surrounding the apolipoprotein E (APOE) gene. APOE was directly genotyped at participant enrollment and we coded APOE- $\epsilon 4+$  versus APOE- $\epsilon 4-$ .

### 2.4. Statistical analysis

Group differences on demographic characteristics were analyzed with  $t$ -test and  $\chi^2$ -tests. Logistic regression models tested whether AD-PRS scores were associated with odds of being in the

AVLT-impaired MCI group. To determine whether the effect of the AD-PRS was driven by the APOE gene, an additional model was run using the “No APOE” AD-PRS and a covariate indicating presence/absence of the APOE- $\epsilon 4$  allele. Models additionally controlled for age and the first 10 genetic principal components to control for population stratification. Analyses were conducted with R version 3.5 (R Core Team, 2017).

## 3. Results

There were no significant between-group differences for sex, education, or American National Adult Reading Test, but the AVLT-normal MCI group was significantly older than the AVLT-impaired MCI group (77 vs. 74 years,  $p < 0.001$ ; Table 1).

Despite the older age of the AVLT-normal group, individuals with higher AD-PRSs were significantly more likely to be in the AVLT-impaired group (odds ratio [OR] = 1.80,  $p < 0.001$ ; Table 2). APOE- $\epsilon 4+$  carriers were more likely to be in the AVLT-impaired group (OR = 2.14,  $p = 0.006$ ). Individuals with higher “No APOE” AD-PRSs were still significantly more likely to be in the AVLT-impaired group (OR = 1.71,  $p < 0.001$ ; Table 2) after controlling for APOE- $\epsilon 4+$  status.

## 4. Discussion

As shown previously, modifying the ADNI criteria for aMCI by requiring impairment on an additional memory test resulted in a higher rate of progression to AD, more pathological levels of amyloid and tau, and more neurodegeneration over time (Vuoksimaa et al., 2018). The difference between the aMCI AVLT-impaired and aMCI AVLT-normal subgroups initially appears to be consistent with the concept of staging, similar to the introduction of early and late MCI diagnoses in ADNI-2 (Aisen et al., 2010). Early versus late MCI in ADNI is determined by magnitude of impairment on a single test, whereas here the groups were classified by impairment on 1 versus 2 tests. The early versus late MCI distinction in ADNI is not a formal diagnostic subcategory. What is most relevant is that the classification assesses the extent of impairment, and the most common interpretations of these distinctions have been based on the notion that the more cognitively impaired group is at a later stage of the same disease trajectory compared to those with less impairment. Anecdotally, we have found that, by far, colleagues most often take this viewpoint in accounting for the greater pathology and progression to AD in the more impaired group. However, the current

**Table 1**

Sample characteristics of MCI subgroups based on the Rey Auditory Verbal Learning Test

n	AVLT-normal 93	AVLT-impaired 225	<i>p</i> value
Age	77.02 (6.96)	73.97 (7.21)	0.001
Gender (male)	62 (66.7%)	149 (66.2%)	1.000
Education (y)	15.84 (2.91)	15.60 (2.94)	0.517
ANART	36.80 (9.66)	36.28 (9.24)	0.655
AVLT trial 1	4.78 (1.73)	3.92 (1.47)	$< 0.001$
AVLT trial 5	9.87 (2.70)	6.48 (1.87)	$< 0.001$
AVLT trials 1–5	38.38 (10.32)	27.44 (6.46)	$< 0.001$
AVLT delayed	6.89 (3.03)	1.08 (1.32)	$< 0.001$

Descriptive statistics at baseline of AVLT-normal (MCI AVLT+) versus AVLT-impaired (MCI AVLT-) MCI groups. Mean (SD) presented for continuous variables, count (%) presented for categorical variables.  $p$ -values are based on  $\chi^2$  tests for categorical variables and  $t$ -tests for continuous variables.

Key: ANART, American National Adult Reading Test (number of correct words); AVLT, Auditory Verbal Learning Test; MCI, mild cognitive impairment; SD, standard deviation.

**Table 2**  
Association of Alzheimer's disease polygenic risk score with MCI subgroups based on the Rey Auditory Verbal Learning Test

Predictors	Odds ratios	95% CI	p value	Predictors	Odds ratios	95% CI	p value
AD-PRS	1.80	1.35–2.38	<0.001	AD-PRS No APOE	1.71	1.28–2.28	<0.001
Age	0.66	0.50–0.87	0.003	APOE-ε4+	2.14	1.24–3.69	0.006
PC 1	1.30	1.00–1.68	0.05	Age	0.68	0.52–0.91	0.008
PC 2	1.16	0.89–1.52	0.281	PC 1	1.20	0.92–1.57	0.184
PC 3	0.96	0.70–1.32	0.803	PC 2	1.17	0.89–1.55	0.26
PC 4	0.97	0.71–1.32	0.844	PC 3	0.98	0.71–1.35	0.881
PC 5	0.92	0.71–1.20	0.544	PC 4	0.97	0.71–1.32	0.836
PC 6	1.03	0.79–1.33	0.839	PC 5	0.92	0.71–1.21	0.557
PC 7	1.00	0.77–1.29	0.97	PC 6	1.00	0.77–1.31	0.983
PC 8	0.81	0.63–1.05	0.12	PC 7	0.99	0.76–1.28	0.914
PC 9	0.80	0.61–1.04	0.099	PC 8	0.82	0.63–1.07	0.139
PC 10	1.19	0.91–1.56	0.199	PC 9	0.79	0.60–1.03	0.086
				PC 10	1.20	0.91–1.58	0.191

Full regression results of logistic regression models. Odds ratios represent the odds of being in the AVLT-impaired group compared to the AVLT-normal group. The table on the left displays results from the model including the full AD-PRS. The table on the right displays results from the “No APOE” AD-PRS which excludes SNPs in the region of the APOE gene as well as a separate variable coding for the presence versus absence of the directly genotyped APOE-ε4+ allele. Both models included age and the first 10 genetic PCs as covariates.

Key: AD-PRS, Alzheimer's disease polygenic risk score; AVLT, Auditory Verbal Learning Test; PC, principal component.

findings indicate that the distinction between early and late MCI groups reflects some excess false positives in the early MCI group.

There appears to be an inherent inconsistency in the aMCI AVLT-normal classification. This inconsistency is reflected in the fact that, if an individual performs normally on the AVLT, it ought to raise serious concerns as to whether they truly have aMCI (i.e., truly have memory impairment). In these analyses, individuals diagnosed as aMCI who had normal performance on the AVLT had significantly lower genetic risk for AD compared with those in the AVLT-impaired MCI group. If they simply happened to be enrolled at different points along their trajectories, there would be no reason for the groups to differ with respect to genetic risk. Although accurate diagnosis can be compromised by ascertainment bias (Storandt and Morris, 2010), this form of ascertainment bias seems unlikely since these ADNI participants were not selected on the basis of AD genetic risk. The significant AD-PRS difference suggests that, rather than representing individuals from the same risk population who are at different points in the disease trajectory, the AVLT-impaired and AVLT-normal groups were drawn from 2 different risk populations. In other words, the AVLT-normal group likely contains more false positives who are not on the AD continuum and/or who are unlikely to develop dementia.

Although cross-sectionally we cannot definitively determine where on the disease trajectory AVLT-impaired individuals fall, we can be more confident that they are experiencing true cognitive impairment. This is consistent with neuropsychological studies which show that determining impairment based on a single test results in excess false positives (Bondi et al., 2014; Edmonds et al., 2015; Jak et al., 2009; Kremen et al., 2014). Incorporating multiple tests has been shown to reduce the number of reversions from MCI to cognitively normal, providing strong evidence that, in these cases, the original diagnoses were false positives (Bondi et al., 2014; Edmonds et al., 2015). Evidence of longitudinal decline is necessary to definitively determine disease staging and rule out false positives that can arise from ascertainment bias (Edmonds et al., 2015, 2016; Storandt and Morris, 2010). For example, it is not possible to distinguish decline from longstanding low performance. However, diagnoses are often based only on the current assessment, so it is important to identify approaches that can reduce misclassification. Our group has found that a composite or factor score of multiple memory tests greatly increases prediction of future decline compared to any single test (Gustavson et al., 2020). We note that in clinical work and in screening of individuals into drug trials, the balance in cost-effectiveness has to be taken into consideration.

Although we believe that the cost of acquiring a comprehensive battery of memory tests is worth the increased sensitivity, our results demonstrate that even 1 additional memory test is valuable.

It is worth noting that the PRS excluding the APOE region was significantly associated with group even after controlling for APOE-ε4 status. This is consistent with findings that the PRS adds significant information above and beyond the APOE genotype (Escott-Price et al., 2015; Logue et al., 2019). A substantial number of APOE-ε4 carriers do not develop AD, and vice versa. That is, non-carriers may still be at risk, and some carriers are at lower risk than others. This result thus underscores the importance of more comprehensively assessing genetic risk for AD, which is a highly polygenic disease. The AD-PRS may include risk genes with pleiotropic effects, and thus may not be entirely specific to AD. However, those with lower AD-PRS should be at lower risk for both AD and any other genetically associated pathology. Put another way, many risk factors for AD are not specific to the disease, but individuals not exposed to that risk factor (or in this case, individuals who do not carry risk alleles) will still have a lower likelihood of developing AD. Moreover, PRSs are still considered useful in assessing risk for the corresponding condition despite the fact that common brain disorders exhibit a high degree of shared genetic influences (Brainstorm et al., 2018).

Another way to reduce false positives and increase diagnostic certainty is in assessing AD-related biomarkers of amyloid or tau. Moscoso et al. (2019) found that, when restricting to those with abnormal amyloid, individuals with greater episodic memory impairment did appear to be in a later stage of MCI. Our results are consistent with this finding in that, when only a single timepoint is available, requiring additional memory tests, evidence of genetic risk, or abnormal biomarkers provides important context to reduce false positives when inferring disease staging. Indeed, by restricting their sample to amyloid-positive subjects, Moscoso et al. minimized the potential for false positives in the early MCI group.

Our results have 2 main implications. First, a small amount of additional memory testing provides a time- and cost-effective method of improving accuracy for the diagnosis of MCI due to AD. Better identification of those who are likely to decline versus remain stable may help patients and families anticipate potential changes in daily functioning. It may also facilitate more sensitive clinical trials by enriching samples for individuals on the AD continuum (i.e., with abnormal AD biomarkers) and those likely to demonstrate cognitive decline within the study timeframe. Second, because genotype information remains constant, it can

provide valuable additional context for interpreting group differences. AD-PRSs determined MCI subgroups with differential risk of disease. Without such genetic information, it is not possible to differentiate early versus late MCI on the basis of cross-sectional data.

### Disclosure statement

The authors report no conflicts of interest.

### CRedit authorship contribution statement

**Jeremy A. Elman:** Conceptualization, Methodology, Formal analysis, Writing - original draft. **Eero Vuoksima:** Conceptualization, Methodology, Writing - review & editing, Funding acquisition. **Carol E. Franz:** Writing - review & editing, Funding acquisition. **William S. Kremen:** Conceptualization, Methodology, Writing - review & editing, Supervision, Funding acquisition.

### Acknowledgements

This work was supported by National Institutes of Health, National Institute on Aging [R01s AG018386, AG022381, AG022982, AG050595, AG018384], National Center for Advancing Translational Science [CTSA grant KL2TR001444]; the Academy of Finland [314639 and 320109], and the Finnish Brain Foundation. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.

### References

- Aisen, P.S., Petersen, R.C., Donohue, M.C., Gamst, A., Raman, R., Thomas, R.G., Walter, S., Trojanowski, J.Q., Shaw, L.M., Beckett, L.A., Jack Jr., C.R., Jagust, W., Toga, A.W., Saykin, A.J., Morris, J.C., Green, R.C., Weiner, M.W., Alzheimer's Disease Neuroimaging, I., 2010. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. *Alzheimers Dement.* 6, 239–246.
- Bondi, M.W., Edmonds, E.C., Jak, A.J., Clark, L.R., Delano-Wood, L., McDonald, C.R., Nation, D.A., Libon, D.J., Au, R., Galasko, D., Salmon, D.P., 2014. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J. Alzheimers Dis.* 42, 275–289.
- Brainstorm, C., Anttila, V., Bulik-Sullivan, B., Finucane, H.K., Walters, R.K., Bras, J., Duncan, L., Escott-Price, V., Falcone, G.J., Gormley, P., Malik, R., Patrapoulos, N.A., Ripke, S., Wei, Z., Yu, D., Lee, P.H., Turley, P., Grenier-Boley, B., Chouraki, V., Kamatani, Y., Berr, C., Letenneur, L., Hannequin, D., Amouyel, P., Boland, A.,

- Deleuze, J.F., Duron, E., Vardarajan, B.N., Reitz, C., Goate, A.M., Huentelman, M.J., Kambh, M.I., Larson, E.B., Rogava, E., St George-Hyslop, P., Hakonarson, H., Kukull, W.A., Farrer, L.A., Barnes, L.L., Beach, T.G., Demirci, F.Y., Head, E., Hulette, C.M., Jicha, G.A., Kauwe, J.S.K., Kaye, J.A., Leverenz, J.B., Levey, A.I., Lieberman, A.P., Pankratz, V.S., Poon, V.W., Quinn, J.F., Saykin, A.J., Schneider, L.S., Smith, A.G., Sonnen, J.A., Stern, R.A., Van Deerlin, V.M., Van Eldik, L.J., Harold, D., Russo, G., Rubinsztein, D.C., Bayer, A., Tsolaki, M., Proitsi, P., Fox, N.C., Hampel, H., Owen, M.J., Mead, S., Passmore, P., Morgan, K., Nothen, M.M., Rossor, M., Lupton, M.K., Hoffmann, P., Kornhuber, J., Lawlor, B., McQuillin, A., Al-Chalabi, A., Bis, J.C., Ruiz, A., Boada, M., Seshadri, S., Beiser, A., Rice, K., van der Lee, S.J., De Jager, P.L., Geschwind, D.H., Riemenschneider, M., Riedel-Heller, S., Rotter, J.I., Ransmayr, G., Hyman, B.T., Cruchaga, C., Alegret, M., Winsvold, B., Palta, P., Farh, K.H., Cuenca-Leon, E., Furlotte, N., Kurth, T., Ligthart, L., Terwindt, G.M., Freilinger, T., Ran, C., Gordon, S.D., Borck, G., Adams, H.H.H., Lehtimäki, T., Wedenoja, J., Buring, J.E., Schurks, M., Hrafnisdottir, M., Hottenga, J.J., Penninx, B., Artto, V., Kaunisto, M., Vepsäläinen, S., Martin, N.G., Montgomery, G.W., Kurki, M.I., Hamalainen, E., Huang, H., Huang, J., Sandor, C., Webber, C., Muller-Myhsok, B., Schreiber, S., Salomaa, V., Loeferer, E., Gobel, H., Macaya, A., Pozo-Rosich, P., Hansen, T., Werge, T., Kaprio, J., Metspalu, A., Kubisch, C., Ferrari, M.D., Belin, A.C., van den Maagdenberg, A., Zwart, J.A., Boomsma, D., Eriksson, N., Olesen, J., Chasman, D.I., Nyholt, D.R., Avbersek, A., Baum, L., Berkovic, S., Bradfield, J., Buono, R., Catarino, C.B., Cossette, P., De Jonghe, P., Depondt, C., Dlugos, D., Ferraro, T.N., French, J., Hjalgrim, H., Jannadas-Khoda, J., Kvaliainen, R., Kunz, W.S., Lerche, H., Leu, C., Lindhout, D., Lo, W., Lowenstein, D., McCormack, M., Moller, R.S., Molloy, A., Ng, P.W., Oliver, K., Privitera, M., Radtke, R., Ruppert, A.K., Sander, T., Schachter, S., Schankin, C., Scheffer, I., Schoch, S., Sisodiya, S.M., Smith, P., Sperling, M., Striano, P., Surges, R., Thomas, G.N., Visscher, F., Whelan, C.D., Zara, F., Heinzen, E.L., Marson, A., Becker, F., Stroink, H., Zimprich, F., Gasser, T., Gibbs, R., Heutink, P., Martinez, M., Morris, H.R., Sharma, M., Ryten, M., Mok, K.Y., Pulit, S., Bevan, S., Holliday, E., Attia, J., Battey, T., Boncoraglio, G., Thijs, V., Chen, W.M., Mitchell, B., Rothwell, P., Sharma, P., Sudlow, C., Vicente, A., Markus, H., Kourkoulis, C., Pera, J., Raffeld, M., Silliman, S., Boraska Perica, V., Thornton, L.M., Huckins, L.M., William Rayner, N., Lewis, C.M., Gratacos, M., Rybakowski, F., Keski-Rahkonen, A., Raevuori, A., Hudson, J.I., Reichborn-Kjennerud, T., Monteleone, P., Karwautz, A., Mannik, K., Baker, J.H., O'Toole, J.K., Trace, S.E., Davis, O.S.P., Helder, S.G., Ehrlich, S., Herpertz-Dahlmann, B., Danner, U.N., van Elburg, A.A., Clementi, M., Forzan, M., Docompo, E., Lissowska, J., Hauser, J., Tortorella, A., Maj, M., Gonidakis, F., Tziouvas, K., Papezova, H., Yilmaz, Z., Wagner, G., Cohen-Woods, S., Herms, S., Julia, A., Rabionet, R., Dick, D.M., Ripatti, S., Andreassen, O.A., Espeseth, T., Lundervold, A.J., Steen, V.M., Pinto, D., Scherer, S., Aschauer, H., Schosser, A., Alfredsson, L., Padyukov, L., Halmi, K.A., Mitchell, J., Strober, M., Bergen, A.W., Kaye, W., Szatkiewicz, J.P., Cormand, B., Ramos-Quiroga, J.A., Sanchez-Mora, C., Ribases, M., Casas, M., Hervas, A., Arranz, M.J., Haavik, J., Zayats, T., Johansson, S., Williams, N., Dempfle, A., Rothenberger, A., Kuntsi, J., Oades, R.D., Banaschewski, T., Franke, B., Buitelaar, J.K., Arias Vasquez, A., Doyle, A.E., Reif, A., Lesch, K.P., Freitag, C., Rivero, O., Palmason, H., Romanos, M., Langley, K., Rietschel, M., Witt, S.H., Dalgaard, S., Borglum, A.D., Waldman, I., Wilmot, B., Molly, N., Bau, C.H.D., Crosbie, J., Schachar, R., Loo, S.K., McGough, J.J., Grevet, E.H., Medland, S.E., Robinson, E., Weiss, L.A., Bacchelli, E., Bailey, A., Bal, V., Battaglia, A., Betancur, C., Bolton, P., Cantor, R., Celestino-Soper, P., Dawson, G., De Rubeis, S., Duque, F., Green, A., Klauck, S.M., Leboyer, M., Levitt, P., Maestrini, E., Mane, S., DeLuca, D.M., Parr, J., Regan, R., Reichenberg, A., Sandin, S., Vorstman, J., Wassink, T., Wijsman, E., Cook, E., Santangelo, S., Delorme, R., Roge, B., Magalhaes, T., Arking, D., Schulze, T.G., Thompson, R.C., Strohmaier, J., Mattheus, K., Melle, I., Morris, D., Blackwood, D., McIntosh, A., Bergen, S.E., Schalling, M., Jamain, S., Maaser, A., Fischer, S.B., Reinbold, C.S., Fullerton, J.M., Guzman-Parra, J., Mayoral, F., Schofield, P.R., Cichon, S., Muhleisen, T.W., Degenhardt, F., Schumacher, J., Bauer, M., Mitchell, P.B., Gershon, E.S., Rice, J., Potash, J.B., Zandi, P.P., Craddock, N., Ferrier, I.N., Alda, M., Rouleau, G.A., Turecki, G., Ophoff, R., Pato, C., Anjorin, A., Stahl, E., Leber, M., Czerni, P.M., Cruceanu, C., Jones, I.R., Posthuma, D., Andlauer, T.F.M., Forstner, A.J., Streit, F., Baune, B.T., Air, T., Sinnamon, G., Wray, N.R., Macintyre, D.J., Porteous, D., Homuth, G., Rivera, M., Grove, J., Middeldorp, C.M., Hickie, I., Pergadia, M., Mehta, D., Smit, J.H., Jansen, R., de Geus, E., Dunn, E., Li, Q.S., Nauck, M., Schoevers, R.A., Beekman, A.T., Knowles, J.A., Viktorin, A., Arnold, P., Barr, C.L., Bedoya-Berrio, G., Bienvenu, O.J., Brentani, H., Burton, C., Camarena, B., Capi, C., Cath, D., Cavallini, M., Cusi, D., Darrow, S., Denys, D., Derks, E.M., Dietrich, A., Fernandez, T., Figee, M., Freimer, N., Gerber, G., Grados, M., Greenberg, E., Hanna, G.L., Hartmann, A., Hirschtritt, M.E., Hoekstra, P.J., Huang, A., Huyser, C., Illmann, C., Jenike, M., Kuperman, S., Leventhal, B., Lochner, C., Lyon, G.J., Macciardi, F., Madruga-Garrido, M., Malaty, I.A., Maras, A., McGrath, L., Miguel, E.C., Mir, P., Nestadt, G., Nicolini, H., Okun, M.S., Pakstis, A., Paschou, P., Piacentini, J., Pittenger, C., Plessen, K., Ramensky, V., Ramos, E.M., Reus, V., Richters, M.A., Riddle, M.A., Robertson, M.M., Roessner, V., Rosario, M., Samuels, J.F., Sandor, P., Stein, D.J., Tsetsos, F., Van Nieuwerburgh, F., Weatherall, S., Wendland, J.R., Wolanczyk, T., Worbe, Y., Zai, G., Goes, F.S., McLaughlin, N., Nestadt, P.S., Grabe, H.J., Depienne, C., Konkashbaev, A., Lanzagorta, N., Valencia-Duarte, A., Bramon, E., Buccola, N., Cahn, W., Cairns, M., Chong, S.A., Cohen, D., Crespo-Facorro, B., Crowley, J., Davidson, M., DeLisi, L., Dinan, T., Donohoe, G., Drapeau, E., Duan, J., Haan, L., Hougaard, D., Karachanak-Yankova, S., Khrunin, A., Klavins, J., Kucinskaskas, V., Lee Chee Keong, J., Limborska, S., Loughland, C., Lonngqvist, J., Maher, B., Mattheisen, M., McDonald, C., Murphy, K.C., Nenadic, I., van Os, J.,

- Pantelis, C., Pato, M., Petryshen, T., Quested, D., Roussos, P., Sanders, A.R., Schall, U., Schwab, S.G., Sim, K., So, H.C., Stogmann, E., Subramaniam, M., Toncheva, D., Waddington, J., Walters, J., Weiser, M., Cheng, W., Cloninger, R., Curtis, D., Gejman, P.V., Henskens, F., Mattingsdal, M., Oh, S.Y., Scott, R., Webb, B., Breen, G., Churchhouse, C., Bulik, C.M., Daly, M., Dichgans, M., Faraone, S.V., Guerreiro, R., Holmans, P., Kendler, K.S., Koelman, B., Mathews, C.A., Price, A., Scharf, J., Sklar, P., Williams, J., Wood, N.W., Cotsapas, C., Palotie, A., Smoller, J.W., Sullivan, P., Rosand, J., Corvin, A., Neale, B.M., Schott, J.M., Anney, R., Elia, J., Grigoriou-Serbanescu, M., Edenberg, H.J., Murray, R., 2018. Analysis of shared heritability in common disorders of the brain. *Science* 360.
- Choi, S.W., O'Reilly, P.F., 2019. PRSice-2: Polygenic Risk Score software for biobank-scale data. *Gigascience* 8, giz082.
- Edmonds, E.C., Delano-Wood, L., Clark, L.R., Jak, A.J., Nation, D.A., McDonald, C.R., Libon, D.J., Au, R., Galasko, D., Salmon, D.P., Bondi, M.W., Alzheimer's Disease Neuroimaging, I., 2015. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. *Alzheimers Dement* 11, 415–424.
- Edmonds, E.C., Delano-Wood, L., Jak, A.J., Galasko, D.R., Salmon, D.P., Bondi, M.W., Alzheimer's Disease Neuroimaging, I., 2016. Missed" mild cognitive impairment: high false-negative error rate based on conventional diagnostic criteria. *J. Alzheimers Dis* 52, 685–691.
- Escott-Price, V., Myers, A.J., Huentelman, M., Hardy, J., 2017. Polygenic risk score analysis of pathologically confirmed Alzheimer's disease. *Ann. Neurol* 82, 311–314.
- Escott-Price, V., Sims, R., Bannister, C., Harold, D., Vronskaya, M., Majounie, E., Badarinarayan, N., Gerad/Perades, consortia, I., Morgan, K., Passmore, P., Holmes, C., Powell, J., Brayne, C., Gill, M., Mead, S., Goate, A., Cruchaga, C., Lambert, J.C., van Duijn, L., Maier, W., Ramirez, A., Holmans, P., Jones, L., Hardy, J., Seshadri, S., Schellenberg, G.D., Amouyel, P., Williams, J., 2015. Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain* 138 (Pt 12), 3673–3684.
- Gustavson, D.E., Elman, J.A., Sanderson-Cimino, M., Franz, C.E., Panizzon, M.S., Jak, A.J., Reynolds, C.A., Neale, M.C., Lyons, M.J., Kremen, W.S., 2020. Extensive memory testing improves prediction of progression to MCI in late middle age. *Alzheimers Dement* 12, e12004.
- Jak, A.J., Bondi, M.W., Delano-Wood, L., Wierenga, C., Corey-Bloom, J., Salmon, D.P., Delis, D.C., 2009. Quantification of five neuropsychological approaches to defining mild cognitive impairment. *Am. J. Geriatr. Psychiatry* 17, 368–375.
- Kremen, W.S., Jak, A.J., Panizzon, M.S., Spoon, K.M., Franz, C.E., Thompson, W.K., Jacobson, K.C., Vasilopoulos, T., Vuoksimaa, E., Xian, H., Toomey, R., Lyons, M.J., 2014. Early identification and heritability of mild cognitive impairment. *Int. J. Epidemiol.* 43, 600–610.
- Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano, A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., Russo, G., Thornton-Wells, T.A., Jones, N., Smith, A.V., Chouraki, V., Thomas, C., Ikram, M.A., Zelenika, D., Vardarajan, B.N., Kamatani, Y., Lin, C.F., Gerrish, A., Schmidt, H., Kunkle, B., Dunstan, M.L., Ruiz, A., Bihoreau, M.T., Choi, S.H., Reitz, C., Pasquier, F., Cruchaga, C., Craig, D., Amin, N., Berr, C., Lopez, O.L., De Jager, P.L., Deramecourt, V., Johnston, J.A., Evans, D., Lovestone, S., Letenneur, L., Moron, F.J., Rubinsztein, D.C., Eiriksdottir, G., Sleegers, K., Goate, A.M., Fievet, N., Huentelman, M.W., Gill, M., Brown, K., Kamboh, M.I., Keller, L., Barberger-Gateau, P., McGuinness, B., Larson, E.B., Green, R., Myers, A.J., Dufouil, C., Todd, S., Wallon, D., Love, S., Rogava, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., Lleo, A., Bayer, A., Tsuang, D.W., Yu, L., Tzolaki, M., Bossu, P., Spalletta, G., Proitsi, P., Collinge, J., Sorbi, S., Sanchez-Garcia, F., Fox, N.C., Hardy, J., Deniz Naranjo, M.C., Bosco, P., Clarke, R., Brayne, C., Galimberti, D., Mancuso, M., Matthews, F., European Alzheimer's Disease, I., Genetic, Environmental Risk in Alzheimer's, D., Alzheimer's Disease Genetic, C., Cohorts for, H., Aging Research in Genomic, E., Moebus, S., Mecocci, P., Del Zompo, M., Maier, W., Hampel, H., Pilotto, A., Bullido, M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J.R., Mayhaus, M., Lannefelt, L., Hakonarson, H., Pichler, S., Carrasquillo, M.M., Ingelsson, M., Beekly, D., Alvarez, V., Zou, F., Valladares, O., Younkin, S.G., Coto, E., Hamilton-Nelson, K.L., Gu, W., Razquin, C., Pastor, P., Mateo, I., Owen, M.J., Faber, K.M., Jonsson, P.V., Combarros, O., O'Donovan, M.C., Cantwell, L.B., Soininen, H., Blacker, D., Mead, S., Mosley Jr, T.H., Bennett, D.A., Harris, T.B., Fratiglioni, L., Holmes, C., de Bruijn, R.F., Passmore, P., Montine, T.J., Bettens, K., Rotter, J.L., Brice, A., Morgan, K., Foroud, T.M., Kukull, W.A., Hannequin, D., Powell, J.F., Nalls, M.A., Ritchie, K., Lunetta, K.L., Kauwe, J.S., Boerwinkle, E., Riemenschneider, M., Boada, M., Hiltunen, M., Martin, E.R., Schmidt, R., Rujescu, D., Wang, L.S., Dartigues, J.F., Mayeux, R., Tzourio, C., Hofman, A., Nothen, M.M., Graff, C., Psaty, B.M., Jones, L., Haines, J.L., Holmans, P.A., Lathrop, M., Pericak-Vance, M.A., Launer, L.J., Farrer, L.A., van Duijn, C.M., Van Broeckhoven, C., Moskvina, V., Seshadri, S., Williams, J., Schellenberg, G.D., Amouyel, P., 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat. Genet.* 45, 1452–1458.
- Logue, M.W., Panizzon, M.S., Elman, J.A., Gillespie, N.A., Hatton, S.N., Gustavson, D.E., Andreassen, O.A., Dale, A.M., Franz, C.E., Lyons, M.J., Neale, M.C., Reynolds, C.A., Tu, X., Kremen, W.S., 2019. Use of an Alzheimer's disease polygenic risk score to identify mild cognitive impairment in adults in their 50s. *Mol. Psychiatry* 24, 421–430.
- Moscato, A., Silva-Rodriguez, J., Aldrey, J.M., Cortes, J., Fernandez-Ferreiro, A., Gomez-Lado, N., Ruibal, A., Aguiar, P., Alzheimer's Disease Neuroimaging, I., 2019. Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory. *Neurobiol. Aging* 84, 1–8.
- Petersen, R.C., Aisen, P.S., Beckett, L.A., Donohue, M.C., Gamst, A.C., Harvey, D.J., Jack Jr., C.R., Jagust, W.J., Shaw, L.M., Toga, A.W., Trojanowski, J.Q., Weiner, M.W., 2010. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology* 74, 201–209.
- R Core Team, 2017. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
- Saykin, A.J., Shen, L., Foroud, T.M., Potkin, S.G., Swaminathan, S., Kim, S., Risacher, S.L., Nho, K., Huentelman, M.J., Craig, D.W., Thompson, P.M., Stein, J.L., Moore, J.H., Farrer, L.A., Green, R.C., Bertram, L., Jack Jr., C.R., Weiner, M.W., Alzheimer's Disease Neuroimaging, I., 2010. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. *Alzheimers Dement* 6, 265–273.
- Storandt, M., Morris, J.C., 2010. Ascertainment bias in the clinical diagnosis of Alzheimer disease. *Arch. Neurol.* 67, 1364–1369.
- The 1000 Genomes Project Consortium, 2015. A global reference for human genetic variation. *Nature* 526, 68–74.
- Vuoksimaa, E., McEvoy, L.K., Holland, D., Franz, C.E., Kremen, W.S., Alzheimer's Disease Neuroimaging, I., 2018. Modifying the minimum criteria for diagnosing amnesic MCI to improve prediction of brain atrophy and progression to Alzheimer's disease. *Brain Imaging Behav.* 4, 1.